Investment Analysts’ Weekly Ratings Changes for Tourmaline Bio (TRML)

Several analysts have recently updated their ratings and price targets for Tourmaline Bio (NASDAQ: TRML):

• 12/11/2024 – Tourmaline Bio had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $25.00 price target on the stock.
• 12/11/2024 – Tourmaline Bio had its “buy” rating reaffirmed by analysts at Guggenheim.
• 12/11/2024 – Tourmaline Bio had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $49.00 price target on the stock.
• 12/6/2024 – Tourmaline Bio is now covered by analysts at BMO Capital Markets. They set an “outperform” rating and a $50.00 price target on the stock.
• 11/11/2024 – Tourmaline Bio had its price target raised by analysts at HC Wainwright from $48.00 to $49.00. They now have a “buy” rating on the stock.

Tourmaline Bio Trading Down 1.3 %

NASDAQ:TRML traded down $0.29 during trading hours on Wednesday, hitting $21.57. 42,815 shares of the company were exchanged, compared to its average volume of 289,793. Tourmaline Bio, Inc. has a one year low of $12.12 and a one year high of $48.31. The company has a fifty day simple moving average of $25.80 and a 200 day simple moving average of $20.03. The stock has a market capitalization of $553.12 million, a price-to-earnings ratio of -7.65 and a beta of 2.32.

Tourmaline Bio (NASDAQ:TRML) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.06. Equities research analysts predict that Tourmaline Bio, Inc. will post -2.99 earnings per share for the current fiscal year.

Institutional Trading of Tourmaline Bio

Several institutional investors have recently made changes to their positions in TRML. Blue Owl Capital Holdings LP lifted its stake in shares of Tourmaline Bio by 18.5% in the 2nd quarter. Blue Owl Capital Holdings LP now owns 1,715,401 shares of the company’s stock valued at $22,060,000 after purchasing an additional 268,000 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Tourmaline Bio in the second quarter valued at approximately $909,000. Rhumbline Advisers increased its stake in shares of Tourmaline Bio by 28,554.3% during the second quarter. Rhumbline Advisers now owns 33,239 shares of the company’s stock valued at $427,000 after buying an additional 33,123 shares during the period. Acuta Capital Partners LLC increased its position in Tourmaline Bio by 23.2% during the 3rd quarter. Acuta Capital Partners LLC now owns 332,095 shares of the company’s stock valued at $8,538,000 after purchasing an additional 62,481 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in Tourmaline Bio by 3.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 63,571 shares of the company’s stock worth $1,634,000 after buying an additional 2,147 shares in the last quarter. Hedge funds and other institutional investors own 91.89% of the company’s stock.

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.